Gut microbiome in chronic kidney disease: challenges and opportunities

Translational Research

Volumn 179, Issue , 2017, Pages 24-37

  Nallu, Anitha ^a   Sharma, Shailendra ^a   Ramezani, Ali ^a   Muralidharan, Jagadeesan ^a   Raj, Dominic ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTESTINE CONTRACTION STIMULATING AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT; UREMIC TOXIN;

BONE MINERALIZATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COMMENSAL; DEPRESSION; DISEASE COURSE; DYSBIOSIS; HIGH FIBER DIET; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INTESTINE FLORA; KIDNEY GRAFT; KWASHIORKOR; MARASMUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; COMPLICATION; HEALTH; MICROBIOLOGY; SYMBIOSIS;

DYSBIOSIS; GASTROINTESTINAL MICROBIOME; HEALTH; HUMANS; IMMUNOMODULATION; RENAL INSUFFICIENCY, CHRONIC; SYMBIOSIS;

EID: 84971668277     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2016.04.007     Document Type: Review

References (184)

1. 1 Sekirov, I., Russell, S.L., Antunes, L.C., et al. Gut microbiota in health and disease. Physiol Rev 90 (2010), 859–904.
2. 2 Hooper, L.V., Midtvedt, T., Gordon, J.I., How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr 22 (2002), 283–307.
3. 3 Hill, M.J., Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev 6 (1997), S43–S45.
4. 4 Hylemon, P.B., Harder, J., Biotransformation of monoterpenes, bile acids, and other isoprenoids in anaerobic ecosystems. FEMS Microbiol Rev 22 (1998), 475–488.
5. 5 Ramezani, A., Massy, Z.A., Meijers, B., et al. Role of the gut microbiome in uremia: a potential therapeutic target. Am J Kidney Dis 67 (2016), 483–498.
6. 6 A framework for human microbiome research. Nature 486 (2012), 215–221.
7. 7 Structure, function and diversity of the healthy human microbiome. Nature 486 (2012), 207–214.
8. 8 Goodrich, J.K., Waters, J.L., Poole, A.C., et al. Human genetics shape the gut microbiome. Cell 159 (2014), 789–799.
9. 9 Thaiss, C.A., Zeevi, D., Levy, M., et al. Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell 159 (2014), 514–529.
10. 10 Muegge, B.D., Kuczynski, J., Knights, D., et al. Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science 332 (2011), 970–974.
11. 11 De, F.C., Cavalieri, D., Di, P.M., et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A 107 (2010), 14691–14696.
12. 12 Podolsky, S.H., Metchnikoff and the microbiome. Lancet 380 (2012), 1810–1811.
13. 13 Bach, J.F., The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347 (2002), 911–920.
14. 14 Penders, J., Thijs, C., van den Brandt, P.A., et al. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut 56 (2007), 661–667.
15. 15 Ley, R.E., Backhed, F., Turnbaugh, P., et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 102 (2005), 11070–11075.
16. 16 Bollyky, P.L., Bice, J.B., Sweet, I.R., et al. The toll-like receptor signaling molecule Myd88 contributes to pancreatic beta-cell homeostasis in response to injury. PLoS One, 4, 2009, e5063.
17. 17 Moore, W.E., Moore, L.H., Intestinal floras of populations that have a high risk of colon cancer. Appl Environ Microbiol 61 (1995), 3202–3207.
18. 18 Chevalier, C., Stojanovic, O., Colin, D.J., et al. Gut microbiota orchestrates energy homeostasis during cold. Cell 163 (2015), 1360–1374.
19. 19 Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 (2006), 1027–1031.
20. 20 Einheber, A., Carter, D., The role of the microbial flora in uremia. I. Survival times of germfree, limited-flora, and conventionalized rats after bilateral nephrectomy and fasting. J Exp Med 123 (1966), 239–250.
21. 21 Yokoyama, M.T., Tabori, C., Miller, E.R., et al. The effects of antibiotics in the weanling pig diet on growth and the excretion of volatile phenolic and aromatic bacterial metabolites. Am J Clin Nutr 35 (1982), 1417–1424.
22. 22 Walser, M., Bodenlos, L.J., Urea metabolism in man. J Clin Invest 38 (1959), 1617–1626.
23. 23 Vaziri, N.D., Dure-Smith, B., Miller, R., et al. Pathology of gastrointestinal tract in chronic hemodialysis patients: an autopsy study of 78 cases. Am J Gastroenterol 80 (1985), 608–611.
24. 24 Stewart, G.S., Smith, C.P., Urea nitrogen salvage mechanisms and their relevance to ruminants, non-ruminants and man. Nutr Res Rev 18 (2005), 49–62.
25. 25 Jones, J.D., Burnett, P.C., Creatinine metabolism in humans with decreased renal function: creatinine deficit. Clin Chem 20 (1974), 1204–1212.
26. 26 Eyk, H.G., van, Vermaat, R.J., et al. The conversion of creatinine by creatininase of bacterial origin. Enzymologia 34 (1968), 198–202.
27. 27 Yokozawa, T., Mo, Z.L., Oura, H., Comparison of toxic effects of methylguanidine, guanidinosuccinic acid and creatinine in rats with adenine-induced chronic renal failure. Nephron 51 (1989), 388–392.
28. 28 Olsen, N.S., Bassett, J.W., Blood levels of urea nitrogen, phenol, guanidine and creatinine in uremia. Am J Med 10 (1951), 52–59.
29. 29 Cummings, J.H., Fermentation in the human large intestine: evidence and implications for health. Lancet 1 (1983), 1206–1209.
30. 30 Wu, I.W., Hsu, K.H., Lee, C.C., et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 26 (2011), 938–947.
31. 31 Lin, C.J., Chen, H.H., Pan, C.F., et al. p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. J Clin Lab Anal 25 (2011), 191–197.
32. 32 Lysaght, M.J., Vonesh, E.F., Gotch, F., et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 37 (1991), 598–604.
33. 33 Motojima, M., Hosokawa, A., Yamato, H., et al. Uraemic toxins induce proximal tubular injury via organic anion transporter 1-mediated uptake. Br J Pharmacol 135 (2002), 555–563.
34. 34 Motojima, M., Hosokawa, A., Yamato, H., et al. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 63 (2003), 1671–1680.
35. 35 Miyazaki, T., Ise, M., Seo, H., et al. Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1 and pro-alpha 1(I) collagen in uremic rat kidneys. Kidney Int Suppl 62 (1997), S15–S22.
36. 36 Adijiang, A., Higuchi, Y., Nishijima, F., et al. Indoxyl sulfate, a uremic toxin, promotes cell senescence in aorta of hypertensive rats. Biochem Biophys Res Commun 399 (2010), 637–641.
37. 37 Barreto, F.C., Barreto, D.V., Liabeuf, S., et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 4 (2009), 1551–1558.
38. 38 Yamamoto, H., Tsuruoka, S., Ioka, T., et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int 69 (2006), 1780–1785.
39. 39 Amabile, N., Guerin, A.P., Leroyer, A., et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 16 (2005), 3381–3388.
40. 40 Dou, L., Bertrand, E., Cerini, C., et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 65 (2004), 442–451.
41. 41 Chiang, C.K., Tanaka, T., Inagi, R., et al. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest 91 (2011), 1564–1571.
42. 42 Nii-Kono, T., Iwasaki, Y., Uchida, M., et al. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 71 (2007), 738–743.
43. 43 Backhed, F., Meat-metabolizing bacteria in atherosclerosis. Nat Med 19 (2013), 533–534.
44. 44 Huang, W.H., Hung, C.C., Yang, C.W., et al. High correlation between clearance of renal protein-bound uremic toxins (indoxyl sulfate and p-cresyl sulfate) and renal water-soluble toxins in peritoneal dialysis patients. Ther Apher Dial 16 (2012), 361–367.
45. 45 Tanaka, H., Iwasaki, Y., Yamato, H., et al. p-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways. Bone 56 (2013), 347–354.
46. 46 Niwa, T., Takeda, N., Tatematsu, A., et al. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography. Clin Chem 34 (1988), 2264–2267.
47. 47 Martinez, A.W., Recht, N.S., Hostetter, T.H., et al. Removal of P-cresol sulfate by hemodialysis. J Am Soc Nephrol 16 (2005), 3430–3436.
48. 48 Satoh, M., Hayashi, H., Watanabe, M., et al. Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure. Nephron Exp Nephrol 95 (2003), e111–e118.
49. 49 De, S.R., Dhondt, A., Eloot, S., et al. Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes. Nephrol Dial Transplant 22 (2007), 2006–2012.
50. 50 Dou, L., Sallee, M., Cerini, C., et al. The cardiovascular effect of the uremic solute indole-3 acetic acid. J Am Soc Nephrol 26 (2015), 876–887.
51. 51 Watanabe, H., Miyamoto, Y., Honda, D., et al. p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int 83 (2013), 582–592.
52. 52 Bammens, B., Evenepoel, P., Keuleers, H., et al. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 69 (2006), 1081–1087.
53. 53 Liabeuf, S., Barreto, D.V., Barreto, F.C., et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 25 (2010), 1183–1191.
54. 54 Cerini, C., Dou, L., Anfosso, F., et al. P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro. Thromb Haemost 92 (2004), 140–150.
55. 55 Meijers, B.K., Evenepoel, P., The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant 26 (2011), 759–761.
56. 56 Niwa, T., Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr 20 (2010), S2–S6.
57. 57 Mutsaers, H.A., Wilmer, M.J., van den Heuvel, L.P., et al. Basolateral transport of the uraemic toxin p-cresyl sulfate: role for organic anion transporters?. Nephrol Dial Transplant, 26, 2011, 4149.
58. 58 Poesen, R., Viaene, L., Verbeke, K., et al. Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD. Clin J Am Soc Nephrol 8 (2013), 1508–1514.
59. 59 Zimmerman, L., Egestad, B., Jornvall, H., et al. Identification and determination of phenylacetylglutamine, a major nitrogenous metabolite in plasma of uremic patients. Clin Nephrol 32 (1989), 124–128.
60. 60 Smith, E.A., MacFarlane, G.T., Formation of phenolic and indolic compounds by anaerobic bacteria in the human large intestine. Microb Ecol 33 (1997), 180–188.
61. 61 Seakins, J.W., The determination of urinary phenylacetylglutamine as phenylacetic acid. Studies on its origin in normal subjects and children with cystic fibrosis. Clin Chim Acta 35 (1971), 121–131.
62. 62 Yang, D., Beylot, M., Agarwal, K.C., et al. Assay of the human liver citric acid cycle probe phenylacetylglutamine and of phenylacetate in plasma by gas chromatography-mass spectrometry. Anal Biochem 212 (1993), 277–282.
63. 63 Schmidt, S., Westhoff, T.H., Krauser, P., et al. The uraemic toxin phenylacetic acid impairs macrophage function. Nephrol Dial Transplant 23 (2008), 3485–3493.
64. 64 Schmidt, S., Westhoff, T.H., Krauser, P., et al. The uraemic toxin phenylacetic acid increases the formation of reactive oxygen species in vascular smooth muscle cells. Nephrol Dial Transplant 23 (2008), 65–71.
65. 65 Yano, S., Yamaguchi, T., Kanazawa, I., et al. The uraemic toxin phenylacetic acid inhibits osteoblastic proliferation and differentiation: an implication for the pathogenesis of low turnover bone in chronic renal failure. Nephrol Dial Transplant 22 (2007), 3160–3165.
66. 66 Remer, T., Manz, F., Paleolithic diet, sweet potato eaters, and potential renal acid load. Am J Clin Nutr 78 (2003), 802–803.
67. 67 Li, M., Wang, B., Zhang, M., et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A 105 (2008), 2117–2122.
68. 68 Cathcart-Rake, W., Porter, R., Whittier, F., et al. Effect of diet on serum accumulation and renal excretion of aryl acids and secretory activity in normal and uremic man. Am J Clin Nutr 28 (1975), 1110–1115.
69. 69 Mitch, W.E., Brusilow, S., Benzoate-induced changes in glycine and urea metabolism in patients with chronic renal failure. J Pharmacol Exp Ther 222 (1982), 572–575.
70. 70 Uremic toxins. Proceedings of the Ghent Symposium. October 3-4, 1986, Ghent, Belgium. Adv Exp Med Biol 223 (1987), 1–296.
71. 71 Igarashi, K., Ueda, S., Yoshida, K., et al. Polyamines in renal failure. Amino Acids 31 (2006), 477–483.
72. 72 Campbell, R.A., Grettie, D.P., Bartos, F., et al. Uremic polyamine dysmetabolism. Proc Clin Dial Transplant Forum 8 (1978), 194–198.
73. 73 Kushner, D., Beckman, B., Nguyen, L., et al. Polyamines in the anemia of end-stage renal disease. Kidney Int 39 (1991), 725–732.
74. 74 Oh, M.S., Phelps, K.R., Traube, M., et al. D-lactic acidosis in a man with the short-bowel syndrome. N Engl J Med 301 (1979), 249–252.
75. 75 Bruckner, H., Hausch, M., Gas chromatographic characterization of free D-amino acids in the blood serum of patients with renal disorders and of healthy volunteers. J Chromatogr 614 (1993), 7–17.
76. 76 Koeth, R.A., Wang, Z., Levison, B.S., et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19 (2013), 576–585.
77. 77 Tang, W.H., Wang, Z., Levison, B.S., et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 368 (2013), 1575–1584.
78. 78 Wang, Z., Klipfell, E., Bennett, B.J., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472 (2011), 57–63.
79. 79 Tang, W.H., Wang, Z., Kennedy, D.J., et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 116 (2015), 448–455.
80. 80 Reiffenstein, R.J., Hulbert, W.C., Roth, S.H., Toxicology of hydrogen sulfide. Annu Rev Pharmacol Toxicol 32 (1992), 109–134.
81. 81 Aminzadeh, M.A., Vaziri, N.D., Downregulation of the renal and hepatic hydrogen sulfide (H2S)-producing enzymes and capacity in chronic kidney disease. Nephrol Dial Transplant 27 (2012), 498–504.
82. 82 Song, K., Wang, F., Li, Q., et al. Hydrogen sulfide inhibits the renal fibrosis of obstructive nephropathy. Kidney Int 85 (2014), 1318–1329.
83. 83 Perna, A.F., Lanza, D., Sepe, I., et al. Hydrogen sulfide, a toxic gas with cardiovascular properties in uremia: how harmful is it?. Blood Purif 31 (2011), 102–106.
84. 84 Rhee, E.P., Clish, C.B., Ghorbani, A., et al. A combined epidemiologic and metabolomic approach improves CKD prediction. J Am Soc Nephrol 24 (2013), 1330–1338.
85. 85 Freudenberg, M.A., Tchaptchet, S., Keck, S., et al. Lipopolysaccharide sensing an important factor in the innate immune response to gram-negative bacterial infections: benefits and hazards of LPS hypersensitivity. Immunobiology 213 (2008), 193–203.
86. 86 Eggesbo, J.B., Hjermann, I., Ovstebo, R., et al. LPS induced procoagulant activity and plasminogen activator activity in mononuclear cells from persons with high or low levels of HDL lipoprotein. Thromb Res 77 (1995), 441–452.
87. 87 Reidy, M.A., Bowyer, D.E., Distortion of endothelial repair. The effect of hypercholesterolaemia on regeneration of aortic endothelium following injury by endotoxin. A scanning electron microscope study. Atherosclerosis 29 (1978), 459–466.
88. 88 Raj, D.S., Shah, V.O., Rambod, M., et al. Association of soluble endotoxin receptor CD14 and mortality among patients undergoing hemodialysis. Am J Kidney Dis 54 (2009), 1062–1071.
89. 89 Poesen, R., Ramezani, A., Claes, K., et al. Associations of soluble CD14 and endotoxin with mortality, cardiovascular disease, and progression of kidney disease among patients with CKD. Clin J Am Soc Nephrol 10 (2015), 1525–1533.
90. 90 Raj, D.S., Carrero, J.J., Shah, V.O., et al. Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. Am J Kidney Dis 54 (2009), 1072–1080.
91. 91 Wikoff, W.R., Anfora, A.T., Liu, J., et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A 106 (2009), 3698–3703.
92. 92 Aronov, P.A., Luo, F.J., Plummer, N.S., et al. Colonic contribution to uremic solutes. J Am Soc Nephrol 22 (2011), 1769–1776.
93. 93 Sorensen, L.B., Role of the intestinal tract in the elimination of uric acid. Arthritis Rheum 8 (1965), 694–706.
94. 94 Gibson, S.A., McFarlan, C., Hay, S., et al. Significance of microflora in proteolysis in the colon. Appl Environ Microbiol 55 (1989), 679–683.
95. 95 Poesen, R., Windey, K., Neven, E., et al. The influence of CKD on colonic microbial metabolism. J Am Soc Nephrol 27 (2016), 1389–1399.
96. 96 Vaziri, N.D., Wong, J., Pahl, M., et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int 83 (2013), 308–315.
97. 97 Wong, J., Piceno, Y.M., Desantis, T.Z., et al. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol 39 (2014), 230–237.
98. 98 Magnusson, M., Magnusson, K.E., Sundqvist, T., et al. Increased intestinal permeability to differently sized polyethylene glycols in uremic rats: effects of low- and high-protein diets. Nephron 56 (1990), 306–311.
99. 99 Magnusson, M., Magnusson, K.E., Sundqvist, T., et al. Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut 32 (1991), 754–759.
100. 100 Vaziri, N.D., Goshtasbi, N., Yuan, J., et al. Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium. Am J Nephrol 36 (2012), 438–443.
101. 101 Vaziri, N.D., Yuan, J., Norris, K., Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol 37 (2013), 1–6.
102. 102 Farhadi, A., Banan, A., Fields, J., et al. Intestinal barrier: an interface between health and disease. J Gastroenterol Hepatol 18 (2003), 479–497.
103. 103 Vaziri, N.D., Yuan, J., Rahimi, A., et al. Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol Dial Transplant 27 (2012), 2686–2693.
104. 104 de Almeida Duarte, J.B., de Aguilar-Nascimento, J.E., Nascimento, M., et al. Bacterial translocation in experimental uremia. Urol Res 32 (2004), 266–270.
105. 105 Szeto, C.C., Kwan, B.C., Chow, K.M., et al. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol 3 (2008), 431–436.
106. 106 Lathrop, S.K., Bloom, S.M., Rao, S.M., et al. Peripheral education of the immune system by colonic commensal microbiota. Nature 478 (2011), 250–254.
107. 107 Cebula, A., Seweryn, M., Rempala, G.A., et al. Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota. Nature 497 (2013), 258–262.
108. 108 Geuking, M.B., Cahenzli, J., Lawson, M.A., et al. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity 34 (2011), 794–806.
109. 109 Zeissig, S., Blumberg, R.S., Commensal microbial regulation of natural killer T cells at the frontiers of the mucosal immune system. FEBS Lett 588 (2014), 4188–4194.
110. 110 Maynard, C.L., Elson, C.O., Hatton, R.D., et al. Reciprocal interactions of the intestinal microbiota and immune system. Nature 489 (2012), 231–241.
111. 111 Clarke, T.B., Davis, K.M., Lysenko, E.S., et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med 16 (2010), 228–231.
112. 112 Mazmanian, S.K., Liu, C.H., Tzianabos, A.O., et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122 (2005), 107–118.
113. 113 Park, J., Kim, M., Kang, S.G., et al. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol 8 (2015), 80–93.
114. 114 Lee, J.R., Muthukumar, T., Dadhania, D., et al. Gut microbial community structure and complications after kidney transplantation: a pilot study. Transplantation 98 (2014), 697–705.
115. 115 Lee, J.R., Muthukumar, T., Dadhania, D., et al. Gut microbiota and tacrolimus dosing in kidney transplantation. PLoS One, 10, 2015, e0122399.
116. 116 Ichii, O., Otsuka-Kanazawa, S., Nakamura, T., et al. Podocyte injury caused by indoxyl sulfate, a uremic toxin and aryl-hydrocarbon receptor ligand. PLoS One, 9, 2014, e108448.
117. 117 Sun, C.Y., Chang, S.C., Wu, M.S., Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS One, 7, 2012, e34026.
118. 118 Wu, X., Ma, C., Han, L., et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 61 (2010), 69–78.
119. 119 Larsen, N., Vogensen, F.K., van den Berg, F.W., et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One, 5, 2010, e9085.
120. 120 Qin, J., Li, Y., Cai, Z., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490 (2012), 55–60.
121. 121 McArdle, M.A., Finucane, O.M., Connaughton, R.M., et al. Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front Endocrinol (Lausanne), 4, 2013, 52.
122. 122 Lee, J., Adipose tissue macrophages in the development of obesity-induced inflammation, insulin resistance and type 2 diabetes. Arch Pharm Res 36 (2013), 208–222.
123. 123 Diamant, M., Blaak, E.E., de Vos, W.M., Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes?. Obes Rev 12 (2011), 272–281.
124. 124 Everard, A., Cani, P.D., Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol 27 (2013), 73–83.
125. 125 Koren, O., Spor, A., Felin, J., et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A 108 (2011), 4592–4598.
126. 126 Wiedermann, C.J., Kiechl, S., Dunzendorfer, S., et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol 34 (1999), 1975–1981.
127. 127 Lin, C.J., Wu, V., Wu, P.C., et al. Meta-analysis of the associations of p-cresyl sulfate (PCS) and indoxyl sulfate (IS) with cardiovascular events and all-cause mortality in patients with chronic renal failure. PLoS One, 10, 2015, e0132589.
128. 128 Wu, I.W., Hsu, K.H., Hsu, H.J., et al. Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients—a prospective cohort study. Nephrol Dial Transplant 27 (2012), 1169–1175.
129. 129 Organ, C.L., Otsuka, H., Bhushan, S., et al. Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure. Circ Heart Fail, 9, 2016, e002314.
130. 130 Miller, P.E., Haberlen, S.A., Brown, T.T., et al. Intestinal microbiota-produced trimethylamine-N-oxide and its association with coronary stenosis and HIV serostatus. J Acquir Immune Defic Syndr 72 (2016), 114–118.
131. 131 Stubbs, J.R., House, J.A., Ocque, A.J., et al. Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. J Am Soc Nephrol 27 (2016), 305–313.
132. 132 Kim, Y.H., Kwak, K.A., Gil, H.W., et al. Indoxyl sulfate promotes apoptosis in cultured osteoblast cells. BMC Pharmacol Toxicol, 14, 2013, 60.
133. 133 Grenham, S., Clarke, G., Cryan, J.F., et al. Brain-gut-microbe communication in health and disease. Front Physiol, 2, 2011, 94.
134. 134 Ohland, C.L., Macnaughton, W.K., Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 298 (2010), G807–G819.
135. 135 Swanson, P.A., Kumar, A., Samarin, S., et al. Enteric commensal bacteria potentiate epithelial restitution via reactive oxygen species-mediated inactivation of focal adhesion kinase phosphatases. Proc Natl Acad Sci U S A 108 (2011), 8803–8808.
136. 136 Shifrin, D.A. Jr., McConnell, R.E., Nambiar, R., et al. Enterocyte microvillus-derived vesicles detoxify bacterial products and regulate epithelial-microbial interactions. Curr Biol 22 (2012), 627–631.
137. 137 Borre, Y.E., O'Keeffe, G.W., Clarke, G., et al. Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol Med 20 (2014), 509–518.
138. 138 Moloney, R.D., Desbonnet, L., Clarke, G., et al. The microbiome: stress, health and disease. Mamm Genome 25 (2014), 49–74.
139. 139 Strachan, D.P., Hay fever, hygiene, and household size. BMJ 299 (1989), 1259–1260.
140. 140 Rook, G.A., Martinelli, R., Brunet, L.R., Innate immune responses to mycobacteria and the downregulation of atopic responses. Curr Opin Allergy Clin Immunol 3 (2003), 337–342.
141. 141 Rook, G.A., Lowry, C.A., Raison, C.L., Microbial ‘Old Friends’, immunoregulation and stress resilience. Evol Med Public Health 2013 (2013), 46–64.
142. 142 Rook, G.A., Raison, C.L., Lowry, C.A., Microbiota, immunoregulatory old friends and psychiatric disorders. Adv Exp Med Biol 817 (2014), 319–356.
143. 143 Smith, M.I., Yatsunenko, T., Manary, M.J., et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science 339 (2013), 548–554.
144. 144 Suau, A., Bonnet, R., Sutren, M., et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol 65 (1999), 4799–4807.
145. 145 Tannock, G.W., Molecular assessment of intestinal microflora. Am J Clin Nutr 73 (2001), 410S–414S.
146. 146 Ding, T., Schloss, P.D., Dynamics and associations of microbial community types across the human body. Nature 509 (2014), 357–360.
147. 147 Shendure, J., Ji, H., Next-generation DNA sequencing. Nat Biotechnol 26 (2008), 1135–1145.
148. 148 Tringe, S.G., Rubin, E.M., Metagenomics: DNA sequencing of environmental samples. Nat Rev Genet 6 (2005), 805–814.
149. 149 Tringe, S.G., von, M.C., Kobayashi, A., et al. Comparative metagenomics of microbial communities. Science 308 (2005), 554–557.
150. 150 Cole, J.R., Chai, B., Farris, R.J., et al. The ribosomal database project (RDP-II): introducing myRDP space and quality controlled public data. Nucleic Acids Res 35 (2007), D169–D172.
151. 151 Lepage, P., Leclerc, M.C., Joossens, M., et al. A metagenomic insight into our gut's microbiome. Gut 62 (2013), 146–158.
152. 152 Rossi, M., Johnson, D.W., Morrison, M., et al. Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial. Clin J Am Soc Nephrol 11 (2016), 223–231.
153. 153 Verberkmoes, N.C., Russell, A.L., Shah, M., et al. Shotgun metaproteomics of the human distal gut microbiota. ISME J 3 (2009), 179–189.
154. 154 Nicholson, J.K., Holmes, E., Wilson, I.D., Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol 3 (2005), 431–438.
155. 155 Jansson, J., Willing, B., Lucio, M., et al. Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS One, 4, 2009, e6386.
156. 156 Le, G.G., Noor, S.O., Ridgway, K., et al. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. J Proteome Res 10 (2011), 4208–4218.
157. 157 Marchesi, J.R., Holmes, E., Khan, F., et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 6 (2007), 546–551.
158. 158 Phua, L.C., Chue, X.P., Koh, P.K., et al. Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther 15 (2014), 389–397.
159. 159 Mutsaers, H.A., Engelke, U.F., Wilmer, M.J., et al. Optimized metabolomic approach to identify uremic solutes in plasma of stage 3-4 chronic kidney disease patients. PLoS One, 8, 2013, e71199.
160. 160 Rastall, R.A., Gibson, G.R., Gill, H.S., et al. Modulation of the microbial ecology of the human colon by probiotics, prebiotics and synbiotics to enhance human health: an overview of enabling science and potential applications. FEMS Microbiol Ecol 52 (2005), 145–152.
161. 161 Konstantinov, S.R., Smidt, H., de Vos, W.M., et al. S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. Proc Natl Acad Sci U S A 105 (2008), 19474–19479.
162. 162 van, B.P., Troost, F.J., van, H.S., et al. Differential NF-kappaB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc Natl Acad Sci U S A 106 (2009), 2371–2376.
163. 163 Ranganathan, N., Patel, B., Ranganathan, P., et al. Probiotic amelioration of azotemia in 5/6th nephrectomized Sprague-Dawley rats. ScientificWorldJournal 5 (2005), 652–660.
164. 164 Chen, L., Liu, W., Li, Y., et al. Lactobacillus acidophilus ATCC 4356 attenuates the atherosclerotic progression through modulation of oxidative stress and inflammatory process. Int Immunopharmacol 17 (2013), 108–115.
165. 165 Prakash, S., Chang, T.M., Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nat Med 2 (1996), 883–887.
166. 166 Pinero-Lambea, C., Ruano-Gallego, D., Fernandez, L.A., Engineered bacteria as therapeutic agents. Curr Opin Biotechnol 35 (2015), 94–102.
167. 167 Mandell, D.J., Lajoie, M.J., Mee, M.T., et al. Corrigendum: biocontainment of genetically modified organisms by synthetic protein design. Nature, 527, 2015, 264.
168. 168 Doi, K., Rabb, H., Impact of acute kidney injury on distant organ function: recent findings and potential therapeutic targets. Kidney Int 89 (2016), 555–564.
169. 169 Ramezani, A., Raj, D.S., The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol 25 (2014), 657–670.
170. 170 Andrade-Oliveira, V., Amano, M.T., Correa-Costa, M., et al. Gut bacteria products prevent AKI induced by ischemia-reperfusion. J Am Soc Nephrol 26 (2015), 1877–1888.
171. 171 Pluznick, J.L., Protzko, R.J., Gevorgyan, H., et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci U S A 110 (2013), 4410–4415.
172. 172 Gibson, G.R., Roberfroid, M.B., Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 125 (1995), 1401–1412.
173. 173 Gibson, G.R., Probert, H.M., Loo, J.V., et al. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev 17 (2004), 259–275.
174. 174 Silk, D.B., Davis, A., Vulevic, J., et al. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 29 (2009), 508–518.
175. 175 Cani, P.D., Neyrinck, A.M., Fava, F., et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50 (2007), 2374–2383.
176. 176 Gibson, G.R., Beatty, E.R., Wang, X., et al. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 108 (1995), 975–982.
177. 177 Pylkas, A.M., Juneja, L.R., Slavin, J.L., Comparison of different fibers for in vitro production of short chain fatty acids by intestinal microflora. J Med Food 8 (2005), 113–116.
178. 178 Krishnamurthy, V.M., Wei, G., Baird, B.C., et al. High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int 81 (2012), 300–306.
179. 179 Meijers, B.K., De Preter, V., Verbeke, K., et al. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant 25 (2010), 219–224.
180. 180 Evenepoel, P., Bammens, B., Verbeke, K., et al. Acarbose treatment lowers generation and serum concentrations of the protein-bound solute p-cresol: a pilot study. Kidney Int 70 (2006), 192–198.
181. 181 Kieffer, D.A., Piccolo, B.D., Vaziri, N.D., et al. Resistant starch alters gut microbiome and metabolomics profiles concurrent with amelioration of chronic kidney disease in rats. Am J Physiol Renal Physiol 310 (2016), F857–F871.
182. 182 Vaziri, N.D., Liu, S.M., Lau, W.L., et al. High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS One, 9, 2014, e114881.
183. 183 Mishima, E., Fukuda, S., Shima, H., et al. Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD. J Am Soc Nephrol 26 (2015), 1787–1794.
184. 184 Wang, Z., Roberts, A.B., Buffa, J.A., et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163 (2015), 1585–1595.